Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 20/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2886254 | 0.92 | PLA2G4A (0.74) | PLA2G4A | |
| SCHEMBL2887837 | 0.88 | PLA2G4A (0.86) | PLA2G4A | |
| SCHEMBL2883509 | 0.88 | PLA2G4A (0.76) | PLA2G4A | |
| SCHEMBL2885116 | 0.88 | PLA2G4A (0.81) | PLA2G4A | |
| SCHEMBL2885667 | 0.86 | PLA2G4A (0.86) | PLA2G4A | |
| SCHEMBL2887261 | 0.86 | PLA2G4A (1.00) | PLA2G4A | |
| SCHEMBL1500832 | 0.86 | PLA2G4A (0.87) | PLA2G4A | |
| SCHEMBL2885619 | 0.86 | PLA2G4A (0.77) | PLA2G4A | |
| SCHEMBL2884383 | 0.85 | PLA2G4A (0.77) | PLA2G4A | |
| SCHEMBL83659 | 0.85 | PLA2G4A (0.77) | PLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029645-A1 | Inhibitors of Cytosolic Phospholipase A2 | WYETH LLC | 2010-02-04 | — | — | US | claimed |
| EP-1891006-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | Wyeth a Corporation of the State of Delaware (US) | 2008-02-27 | — | — | EP | claimed |
| US-20070004719-A1 | Inhibitors of cytosolic phospholipase A2 | WYETH (US) | 2007-01-04 | — | — | US | claimed |
| WO-2006128142-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH (US) | 2006-11-30 | — | — | WO | claimed |
| US-8283373-B2 | Inhibitors of cytosolic phospholipase A2 | PFIZER INC. (US) | 2012-10-09 | — | — | US | disclosed |
| EP-1891006-B1 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH LLC (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-2248801-A1 | Inhibitors of cytosolic phospholipase a2 | Wyeth LLC (US) | 2010-11-10 | — | — | EP | disclosed |
| US-20100113443-A1 | LIQUID FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS | WYETH (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113443-A1 | LIQUID FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS | WYETH (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100093725-A1 | SEMI-SOLID FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS | WYETH | 2010-04-15 | — | — | US | disclosed |
| US-20100093725-A1 | SEMI-SOLID FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS | WYETH | 2010-04-15 | — | — | US | disclosed |
| US-20100069385-A1 | LIQUID FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS | WYETH (NJ) | 2010-03-18 | — | — | US | disclosed |
| WO-2008055146-A9 | FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS | WYETH CORP (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008055148-A2 | SEMI-SOLID FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS | WYETH (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008055146-A2 | FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS | WYETH (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008055136-A2 | LIQUID FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS | WYETH (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008055141-A2 | LIQUID FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS | WYETH (US) | 2008-05-08 | — | — | WO | disclosed |
| EP-1891006-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | Wyeth a Corporation of the State of Delaware (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070004719-A1 | Inhibitors of cytosolic phospholipase A2 | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006128142-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093725-A1 | SEMI-SOLID FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS | PLA2G4A, PLA2G2D, PLA2G4B | PLA2G4A 1/4885 |
| US-20100113443-A1 | LIQUID FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS | PLA2G4B, PLA2G4A, PLA2G1B | PLA2G4A 2/4885 |
| US-20100069385-A1 | LIQUID FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS | PLA2G2D, PLA2G4B, PLA2G4A | PLA2G4A 3/4885 |
| US-20100029645-A1 | Inhibitors of Cytosolic Phospholipase A2 | PLA2G4B, PLA2G4A, PLA2G12A | PLA2G4A 2/4885 |
| US-20070004719-A1 | Inhibitors of cytosolic phospholipase A2 | PLA2G4B, PLA2G4A, PLA2G12A | PLA2G4A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.